SCHEMBL14839156

SCHEMBL14839156

CC(C)n1cnc2c(Nc3nc(N[C@@H]4CCCC[C@@H]4N)nnc3C(N)=O)cccc21

nearest known ligand 0.66

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ SYK P43405 20/20 0.66
▸ KCNH2 Q12809 2/20 0.60
▸ BUB1 O43683 1/20 0.60
▸ JAK2 O60674 1/20 0.60
▸ PAK4 O96013 1/20 0.60
▸ ROS1 P08922 1/20 0.60
▸ AXL P30530 1/20 0.60
▸ ZAP70 P43403 1/20 0.60
▸ IRAK1 P51617 1/20 0.60
▸ MERTK Q12866 1/20 0.60
▸ SLK Q9H2G2 1/20 0.60
▸ PAK6 Q9NQU5 1/20 0.60
▸ PAK5 Q9P286 1/20 0.60
▸ MAP3K2 Q9Y2U5 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14839134 0.89 SYK (0.76) SYKKCNH2BUB1JAK2PAK4
SCHEMBL15910899 0.86 SYK (0.85) SYKKCNH2
SCHEMBL14839220 0.82 SYK (0.80) SYKKCNH2BUB1JAK2PAK4
SCHEMBL15910600 0.80 SYK (1.00) SYKKCNH2
SCHEMBL14838897 0.79 SYK (1.00) SYKKCNH2BUB1JAK2PAK4
SCHEMBL14839001 0.79 SYK (1.00) SYKKCNH2
SCHEMBL15935634 0.79 SYK (0.64) SYKKCNH2BUB1JAK2PAK4
SCHEMBL16253414 0.78 SYK (0.82) SYKKCNH2
SCHEMBL14839008 0.78 SYK (0.73) SYKKCNH2BUB1JAK2PAK4
SCHEMBL15910966 0.78 SYK (1.00) SYKKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9145414-B2 1,2,4-triazine-6-carboxamide derivative TAIHO PHARMACEUTICAL CO., LTD. (JP) 2015-09-29 — — US disclosed
US-9145414-B2 1,2,4-triazine-6-carboxamide derivative TAIHO PHARMACEUTICAL CO., LTD. (JP) 2015-09-29 — — US disclosed
US-20140343038-A1 1,2,4-TRIAZINE-6-CARBOXAMIDE DERIVATIVE TAIHO PHARMACEUTICAL CO., LTD. (JP) 2014-11-20 — — US disclosed
US-20140343038-A1 1,2,4-TRIAZINE-6-CARBOXAMIDE DERIVATIVE TAIHO PHARMACEUTICAL CO., LTD. (JP) 2014-11-20 — — US disclosed
EP-2762476-A1 1,2,4-TRIAZINE-6-CARBOXAMIDE DERIVATIVE Taiho Pharmaceutical Co., Ltd. (JP) 2014-08-06 — — EP disclosed
WO-2013047813-A1 1,2,4-TRIAZINE-6-CARBOXAMIDE DERIVATIVE 大鵬薬品工業株式会社 (JP) 2013-04-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140343038-A1 1,2,4-TRIAZINE-6-CARBOXAMIDE DERIVATIVE SYK, BTK, JAK2 SYK 1/4885KCNH2 146/4885BUB1 1590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback